There’s nonetheless quite a bit we don’t know on the subject of GLP-1s. How do these medicine’ unwanted side effects range throughout completely different sufferers? How efficient are these drugs in the long run? Are limitations to GLP-1s worsening well being inequities?
On Tuesday, OMNY Well being — a nationwide knowledge ecosystem that facilitates biotech and medical analysis — launched a knowledge community that may assist reply a few of these questions.
The brand new knowledge community seeks to present OMNY’s life sciences and well being system companions an enormous supply of GLP-1 knowledge that’s associated to affected person demographics and social determinants of well being, stated OMNY CEO Mitesh Rao.
“It is very important acknowledge that these drugs have an effect on each a part of the physique. With numerous and complete knowledge, clinicians can ship extra equitable therapy plans that replicate the bigger systemic influence they’ve on the entire physique. Researchers can even be capable to higher perceive how the drugs have an effect on broader well being outcomes,” he defined.
The brand new knowledge community consists of EHR knowledge from greater than 645,000 sufferers. This affected person inhabitants represents a broad set of demographic traits, together with age ranges, race, ethnicity, and area of care supply, in addition to supplier and payer sorts, Rao famous.
He stated that one of many GLP-1 knowledge community’s principal objectives is to tell medical trials with numerous populations, enabling clinicians to make extra knowledgeable choices on methods to incorporate these drugs into their sufferers’ care.
OMNY lately used its new GLP-1 knowledge community to conduct two research with life sciences companions, Rao identified.
Considered one of these centered on pediatric use of GLP-1s, which was not authorized by FDA till December 2022. It discovered that the median age of pediatric GLP-1 customers was 16 years, and the vast majority of these sufferers (72%) have been feminine, he acknowledged. The opposite examine, which centered on social determinants of well being, found that GLP-1 sufferers have been half as prone to have financial burden points famous of their EHR report in comparison with the inhabitants of non-users, he added.
“The information community will present well timed and complete perception into how sufferers are navigating GLP-1 drugs, permitting clinicians to higher optimize care plans and outcomes,” he stated. “It can permit researchers to higher perceive the influence of those drugs on total well being past weight reduction, and supply a deeper view into how parts like social determinants have an effect on the well being outcomes of sufferers on GLP-1s.”
The rising demand for GLP-1s has made the necessity for complete knowledge on the drug class extra pressing than ever, Rao famous. A KFF Well being Monitoring Ballot from Might discovered that 12% U.S. adults stated they’ve taken a GLP-1 drug.
Photograph: Natali_Mis, Getty Photographs
